Cardinal Health Sheds its China Operations
Cardinal Health Inc. (NYSE: CAH) put its Cardinal Health China business up for sale in July of this year, following concerns that upcoming drug distribution reform could threaten the company’s growth. Cardinal’s China business is the eighth largest drug distributor in the country, operating 14 direct sales units and 17 distribution centers that cover 322 cities and 11,000 medical institutions. The bidding process was very competitive, according to Reuters, and names like Warburg Pincus were rumored to have competed in the final rounds, among other private equity and Chinese pharmaceutical bidders. On November 14th, Cardinal Health announced that Shanghai Pharmaceuticals Holding Co., Ltd.... Read More »
Telehealth Deals Dial Up in Early 2017
Three telehealth deals have been announced in the first six weeks of 2017, an indication that this sub-sector of digital health is on track to set a(nother) M&A record. In 2016, eight of these deals were announced, an increase of 100% compared with 2014 and 60% versus 2015. Telehealth is loosely defined as the use of technology to support long-distance clinical healthcare. Some examples include live video between a patient and healthcare provider, transmission of medical images to a specialist, and remote monitoring which allows patients and providers to track vitals and manage chronic conditions. On February 2nd, 2017, Specialists On Call, Inc., a portfolio company of Warburg Pincus... Read More »
Werfen Life Divests to Focus on the Hemostasis Market
The growing prevalence of autoimmune and blood disorders has put a spotlight on the science of hemostasis, the process of stopping bleeding and keeping blood within the damaged blood vessel. The coagulation/hemostasis analyzer market is expected to reach $4.84 billion by 2021, according to a report from MarketsandMarkets. Among the products, clinical laboratory analyzers are expected to account for the largest share of the market. Some big name players are already strengthening their hemostasis portfolios. In December 2015, Mallinckrodt plc (NYSE: MNK) purchased a global portfolio of three hemostasis products from The Medicines Company (NASDAQ: MDCO) for an upfront payment of $175... Read More »PE Firms Target Revenue Cycle Management
Follow the money. Everywhere in health care today, controlling the flow of revenue is critical to success, from physician practices to hospitals, skilled nursing facilities and more. As critical as it is, revenue cycle management took a back seat to electronic medical records in recent years, as CMS enforced the early stages of Meaningful Use to get physician practices on board with EMRs. Now that the switch to the ICD-10 coding system is firmly in place, investors’ attention has turned back to revenue cycle management (RCM). In just the first four months of 2016, nine RCM companies have been acquired, surpassing 2014’s total of eight RCM deals, and putting this year on track to beat... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
